| Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study | |
| 2022-06-01 | |
| Source Publication | HEPATOLOGY INTERNATIONAL
 |
| ISSN | 1936-0533 |
| Volume | 16Issue:3Pages:691-701 |
| Abstract | Background Data on safety and immunogenicity of coronavirus disease 2019 (COVID-19) vaccination in patients with compensated (C-cirrhosis) and decompensated cirrhosis (D-cirrhosis) are limited. Methods In this prospective multicenter study, adult participants with C-cirrhosis and D-cirrhosis were enrolled and received two doses of inactivated whole-virion COVID-19 vaccines. Adverse events were recorded within 14 days after any dose of vaccination, and serum samples of enrolled patients were collected and tested for SARS-CoV-2 neutralizing antibodies at least 14 days after the second dose. Risk factors for negative neutralizing antibody were analyzed. Results In total, 553 patients were enrolled from 15 centers in China, including 388 and 165 patients with C-cirrhosis and D-cirrhosis. The vaccines were well tolerated, most adverse reactions were mild and transient, and injection site pain (23/388 [5.9%] vs 9/165 [5.5%]) and fatigue (5/388 [1.3%] vs 3/165 [1.8%]) were the most frequently local and systemic adverse events in both the C-cirrhosis and D-cirrhosis groups. Overall, 4.4% (16/363) and 0.3% (1/363) of patients were reported Grades 2 and 3 alanine aminotransferase (ALT) elevations (defined as ALT > 2 upper limit of normal [ULN] but <= 5 ULN, and ALT > 5 ULN, respectively). The positive rates of COVID-19 neutralizing antibodies were 71.6% (278/388) and 66.1% (109/165) in C-cirrhosis and D-cirrhosis groups. Notably, Child-Pugh score of B and C levels was an independent risk factor of negative neutralizing antibody. Conclusions Inactivated COVID-19 vaccinations are safe with acceptable immunogenicity in cirrhotic patients, and Child-Pugh score of B and C levels is associated with hyporesponsive to COVID-19 vaccination. |
| Keyword | Child-Pugh Compensated cirrhosis Coronavirus disease 2019 Decompensated cirrhosis Hepatitis B virus Immunogenicity Safety Severe acute respiratory syndrome coronavirus 2 Vaccine Vaccination |
| Publisher | SPRINGER |
| DOI | 10.1007/s12072-022-10332-9 |
| Indexed By | SCIE |
| Language | 英语 |
| WOS Research Area | Gastroenterology & Hepatology |
| WOS Subject | Gastroenterology & Hepatology |
| WOS ID | WOS:000780665500001 |
| Original Document Type | Article |
| Citation statistics | |
| Document Type | 期刊论文 |
| Identifier | https://ir.lzu.edu.cn/handle/262010/481070 |
| Collection | 兰州大学 |
| Affiliation | 1.Southeast Univ, Zhongda Hosp, Sch Med, Dept Radiol, Nanjing, Jiangsu, Peoples R China; 2.Xingtai Peoples Hosp, CHESS COVID 19 Grp, Xingtai, Hebei, Peoples R China; 3.Fudan Univ, Dept Infect Dis, Huashan Hosp, Shanghai, Peoples R China; 4.Third Cent Hosp Tianjin, Dept Hepatol & Gastroenterol, Tianjin, Peoples R China; 5.Sixth Peoples Hosp Shenyang, CHESS COVID 19 Grp, Shenyang, Liaoning, Peoples R China; 6.Third Peoples Hosp Taiyuan, Dept Hepatol, Taiyuan, Shanxi, Peoples R China; 7.Lishui Peoples Hosp, Dept Infect Dis, Lishui, Zhejiang, Peoples R China; 8.Peking Univ, Dept Microbiol, Hlth Sci Ctr, Beijing, Peoples R China; 9.Peking Univ, Infect Dis Ctr, Sch Basic Med Sci, Hlth Sci Ctr, Beijing, Peoples R China; 10.Lishui Peoples Hosp, Clinal Lab, Lishui, Zhejiang, Peoples R China; 11.Nanjing Univ Chinese Med, Dept Infect Dis, Nanjing Hosp Chinese Med, Nanjing, Jiangsu, Peoples R China; 12.Baoding Peoples Hosp, Dept Gastroenterol, Baoding, Heibei, Peoples R China; 13.Qingdao Univ, Liver Dis Ctr, Div Hepatol, Affiliated Hosp, Qingdao, Shandong, Peoples R China; 14.Dalian Med Univ, Liver Dis Ctr Integrated Tradit Chinese & Western, Dept Infect Dis, Affiliated Hosp 1, Dalian, Liaoning, Peoples R China; 15.Jincheng Peoples Hosp, Dept Hepatobiliary Surg, Jincheng, Shanxi, Peoples R China; 16.Fourth Peoples Hosp Qinghai Prov, Dept Gastroenterol, Xining, Qinghai, Peoples R China; 17.Third Peoples Hosp Linfen City, Dept Liver Dis, Linfen, Shanxi, Peoples R China; 18.Jiangnan Univ, CHESS COVID 19 Grp, Peoples Hosp Wuxi 5, Affiliated Hosp, Wuxi, Jiangsu, Peoples R China; 19.Peoples Hosp Ningxia Hui Autonomous Reg, CHESS COVID 19 Grp, Yinchuan, Ningxia, Peoples R China; 20.Zhejiang Univ, Lishui Hosp, CHESS COVID 19 Grp, Lishui, Zhejiang, Peoples R China; 21.Jiangsu Univ, Dept Hepatol, Zhenjiang Hosp 3, Zhenjiang, Jiangsu, Peoples R China; 22.Chongqing Med Univ, Dept Gastroenterol, Affiliated Hosp 2, Chongqing, Peoples R China; 23.Third Peoples Hosp Tibet Autonomous Reg, CHESS COVID 19 Grp, Lhasa, Tibet Autonomou, Peoples R China; 24.Lanzhou Univ, Dept Infect Dis, Hosp 1, Lanzhou, Gansu, Peoples R China; 25.Southwest Med Univ, Dept Gastroenterol, Affiliated Hosp, Luzhou, Sichuan, Peoples R China; 26.Zhengzhou Univ, Dept Infect Dis & Hepatol, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China |
| Recommended Citation GB/T 7714 | Wang, Jitao,Zhang, Qiran,Ai, Jingwen,et al. Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study[J]. HEPATOLOGY INTERNATIONAL,2022,16(3):691-701. |
| APA | Wang, Jitao.,Zhang, Qiran.,Ai, Jingwen.,Liu, Dengxiang.,Liu, Chuan.,...&Zhang, Wenhong.(2022).Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study.HEPATOLOGY INTERNATIONAL,16(3),691-701. |
| MLA | Wang, Jitao,et al."Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study".HEPATOLOGY INTERNATIONAL 16.3(2022):691-701. |
| Files in This Item: | There are no files associated with this item. | ||||
